JAZZ PHARMACEUTICALS SOBRE LOS RIESGOS E INCERTIDUMBRES CON LURBINECTEDIN ( ZEPZELCA ) ... : PREVEMOS QUE LURBINECTEDIN ( ZEPZELCA ) COMPITA CON PRODUCTOS GENÉRICOS EN EL FUTURO .
... Yondelis is a key product for the loss-making Spanish company, which forecasts that sales of the drug could reach 300 million euros ($420.3 million) a year in Europe. ...